Carotenoids and retinoids: A review of research, clinical, and public health applications

Journal of Clinical Pharmacology

Volumn 37, Issue 7, 1997, Pages 551-558

  Hinds, Tanya S ^a   West, William L ^a   Knight, Enid M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAROTENOID; RETINOID;

CANCER; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CORONARY RISK; DRUG USE; HUMAN; REVIEW; VITAMIN INTAKE; VITAMIN METABOLISM;

EID: 0030769412     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04336.x     Document Type: Review

References (54)

1. Zeng S, Furr HC, Olson JA: Metabolism of carotenoid analogues in humans. Am J Clin Nutr 1992;56:433-439.
2. Kostic D, White WS, Olson JA: Intestinal absorption, serum clearance, and interactions between lutein and beta carotene when administered to human adults in separate or combined oral doses. Am J Clin Nutr 1995;62:604-610.
3. Wang XD, Tang GW, Fox JG, et al: Enzymatic conversion of beta carotene into beta-apocarotenals and retinoids by human, monkey, ferret, and rat tissues. Arch Biochem Biophys 1991; 285:8-16.
4. Ong D: Retinoid metabolism during intestinal absorption. J Nutr 1993;123:351-355.
5. Bloomhoff R, Green M, Green J, et al: Vitamin A metabolism: new perspectives on absorption, transport and storage. Physiol Rev 1991;71:951-990.
6. Skrede B, Bloomhoff R, Maelandsmo G, et al: Uptake of chylomicron remnant retinyl esters in human leukocytes in vivo. Eur J Clin Invest 1992;22:229-234.
7. Wathne K, Norum K, Smeland E, et al: Retinol bound to physiological carrier molecules regulates growth and differentiation of myeloid leukemic cells. J Biol Chem 1988;263:8691-8695.
8. Raica N, Scott J, Lowry L: Vitamin A concentration in human tissues collected from five areas in the United States. Am J Clin Nutr 1972;25:291-296.
9. Marcus R, Coulston A: Fat-soluble vitamins A, K, E. In, Gilman A. Rall T, Nies A, Taylor P (eds.): Goodman and Gilman's Pharmacological Basis of Therapeutics. Eighth Edition. New York: Pergamon Press, 1990.
10. National Research Council: Recommended Dietary Allowances. Tenth Edition. Washington, DC: National Academy Press, 1989.
11. Kardinaal AF, Aro A, Kark JD, et al: Association between beta-carotene and acute myocardial infarction depends on polyunsaturated fatty acid status. Arterioscler Thromb Vasc Biol 1995; 15:726-732.
12. Todd S, Woodward M, Bolton-Smith C: An investigation of the relationship between antioxidant vitamin intake and coronary heart disease in men and women using logistic regression analysis. J Clin Epidemiol 1995;48:307-316.
13. Sahyoun N, Jacques P, Russe RM: Carotenoids, vitamin C and E, and mortality in an elderly population. Am J Epidemiol 1996; 144:501-511.
14. Gaziano JM, Manson JE, Branch LG, et al: A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 1995;5:255-260.
15. Hennekens C, Buring J, Manson J, et al: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-1149.
16. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-1155.
17. Kushi LH, Folsom AR, Prineas RJ, et al: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156-1162.
18. Steinmetz KA, Potter JD: Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 1996;96:1027-1039.
19. Symposium on antioxidant vitamins and beta carotene. Am J Clin Nutr 1991;53(suppl):1S-396S.
20. Willett WC, Hunter DJ: Vitamin A and cancers of the breast, large bowel, and prostate: epidemiologic evidence. Nutr Rev 1994;52:S53-S59.
21. Blot WJ, Li JY, Taylor PR, et al: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1492.
22. Zheng W, Sellers TA, Doyle TJ, et al: Retinol, antioxidant vitamins, and cancers of the upper digestive tract in a prospective cohort study of postmenopausal women. Am J Epidemiol 1995;142:955-960.
23. Greenberg ER, Baron JA, Tosteson TD, et al: A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 1994;331:141-147.
24. The Alpha Tocopherol, Beta Carotene Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-1035.
25. Giovannucci E, Ascherio A, Rimm E, et al: Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767-1776.
26. Levy J, Bosin E, Feldman B, et al: Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha carotene or beta carotene. Nutr Cancer 1995;24:257-266.
27. Studer U, Jenzer S, Biedermann C, et al: Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors: final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995;28:284-290.
28. Sitzmann J, Bauer F, Cunliffe W, et al: In situ hybridization analysis of CRABP II expression in sebaceous follicles from 13-cis-retinoic acid treated acne patients. Br J Dermatol 1995; 133:241-248.
29. Dahiya R, Park H, Cusick J, et al: Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 1994;59:126-132.
30. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
31. Maeda Y, Miyatake J, Sono H, et al: 13-cis retinoic acid inhibits growth of adult T cell leukemia cells and causes apoptosis; possible new indication for retinoid therapy. Intern Med 1996; 35:180-184.
32. Eisenhauer EA, Lippman SM, Kavanagh JJ, et al: Combination of 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia 1994;8:1622-1625.
33. Fierlbeck G, Schreiner T, Rassner G: Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for treatment of metastatic melanoma. Cancer Immunol Immunother 1995;40:157-164.
34. Markowska J, Nowak M, Niecewicz R, et al: Results of topical treatment of HPV infection in the uterine cervix using interferon beta, 13-cis-retinoic acid and TFX. Eur J Gynaecol 1994;15:65-69.
35. Lama G, Angelucci C, Recchia F, et al: Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Cancer Lett 1996;100:181-189.
36. Warrell RP, Frankel SR, Miller WH, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385-1393.
37. Meyskens FL, Surwit E, Moon TE, et al: Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994;86:539-543.
38. Geiger J: Retinoids and sebaceous gland activity. Dermatol 1995;191:305-310.
39. Griffiths C, Kang S, Ellis C, et al: Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation: a double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. Arch Dermatol 1995;131:1037-1044.
40. Shalita A, Weiss JS, Chalker DK, et al: A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne: a multicenter trial. J Am Acad Dermatol 1996;34:482-485.
41. Zhu J, Shi X, Chu H, et al: Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. Leukemia 1995;9:302-309.
42. Sass J, Masgrau E, Saurat J, et al: Metabolism of oral 9-cis-retinoic acid in the human: identification of 9-cis-retinoyl-beta-glucuronide and 9-cis-4-oxo-retinoyl-beta-glucuronide as urinary metabolites. Drug Metab Dispos 1995;23:887-891.
43. Anzano MA, Byers SW, Smith JM, et al: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994;54:4614-4617.
44. Geiger J, Baudin M, Saurat J: Teratogenic risk with etretinate and acitretin treatment. Dermatol 1994;189:109-116.
45. Lacour M, Mehta-Nikhar B, Atherton DJ, et al: An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol 1996;134:1023-1029.
46. Cobleigh MA, Dowlatshahi K, Deutsch TA, et al: Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 1993; 11:474-477.
47. Dew SE, Wardlaw SA, Ong DE: Effects of pharmacological retinoids on several vitamin A metabolizing enzymes. Cancer Res 1993;53:2965-2969.
48. Ponzoni M, Bocca P, Chiesa V, et al: Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55:853-861.
49. Tradati N, Chiesa F, Rossi N, et al: Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett 1994;76:109-111.
50. Chiesa F, Tradati N, Marazza M, et al: Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem (Suppl) 1993;17F:S255-S261.
51. Abou-Issa H, Curley RW, Panigot MJ, et al: In vivo use of N-(4-hydroxy phenyl retinamide)-O-glucuronide as a breast cancer chemopreventive agent. Anticancer Res 1993;13:1431-1436.
52. Tanaka T, Makita H, Ohnishi M, et al: Inhibition of oral carcinogenesis by the arotinoid mafarotene (Ro 40-8757) in male F344 rats. Carcinogenesis 1995;16:1903-1907.
53. Eliason J, Inoue T, Kubota A, et al: The anti-tumor arotinoid Ro 40-8757 protects bone marrow from the toxic effects of 5-fluorouracil. Int J Cancer 1994;57:192-197.
54. Louvet C, Djelloul S, Forgue-Lafitte ME, et al: Antiproliferative effects of the arotinoid Ro 40-8757 in human gastrointestinal and pancreatic cancer cell lines: combinations with 5-fluorouracil and interferon-alpha. Br J Cancer 1996;74:394-399.